Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsDRUGDOCS AIAboutNewsGlossaryContact
HomeDrugsAIAboutNewsGlossaryContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

AI

News

Mosunetuzumab-axgb

(Lunsumio®)

Lunsumio®

Drug updated on 9/4/2024

Dosage FormInjection (intravenous; 1 mg/mL, 30 mg/30 mL [1 mg/mL] single-dose vials)
Drug ClassCD20-directed CD3 T-cell engagers
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • For the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Lunsumio (mosunetuzumab-axgb) is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
  • This summary is based on the review of two systematic review(s)/meta-analysis(es). [1-2]
  • Overall Response Rate (ORR) and Complete Response (CR): Mosunetuzumab demonstrated an ORR of 80% and a CR rate of 60% in the clinical trial cohort, compared to an ORR of 75% and a CR rate of 33% in the real-world data (RWD) cohort.
  • Progression-Free Survival (PFS) and Overall Survival (OS): Mosunetuzumab had a hazard ratio for PFS of 0.82 (95% CI, 0.53-1.27) and for OS of 0.43 (95% CI, 0.19-0.94) when compared to a RWD cohort, with MAIC results favoring mosunetuzumab over tazemetostat in EHZ2wild-type patients and PI3K inhibitors for CR, ORR, discontinuations due to adverse events, and PFS.
  • Comparisons with Other Therapies: Mosunetuzumab showed superior outcomes compared to tazemetostat in EHZ2wild-type patients for all effectiveness measures and better outcomes than PI3K inhibitors for CR, ORR, discontinuations due to adverse events, and PFS, with mixed results observed against anti-CD20 antibody-based regimens and CART therapies.
  • There is no detailed safety information available in the reviewed studies.
  • Mosunetuzumab had fewer discontinuations due to adverse events compared to PI3K inhibitors, as noted in the MAIC results.
  • The reviewed studies focus on patients with relapsed/refractory follicular lymphoma (RR FL) who have undergone two or more prior lines of therapy, with specific findings indicating that mosunetuzumab shows superior effectiveness in EHZ2wild-type patients compared to tazemetostat.